Sugi Predict

Sugi Predict / Compounds / SCHEMBL7618989

SCHEMBL7618989

SCHEMBL7618989

Cc1ccc(-c2cnc3c(-c4ccncc4)cnn3c2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 18/20 1.00
▸ FLT1 P17948 5/20 0.83
▸ FLT4 P35916 4/20 0.83
▸ BMP4 P12644 5/20 0.74
▸ PRKAB2 O43741 2/20 0.57
▸ LCK P06239 2/20 0.57
▸ SRC P12931 2/20 0.57
▸ EPHA2 P29317 2/20 0.57
▸ PRKAG1 P54619 2/20 0.57
▸ PRKAA2 P54646 2/20 0.57
▸ PRKAA1 Q13131 2/20 0.57
▸ RPS6KA1 Q15418 2/20 0.57
▸ MKNK1 Q9BUB5 2/20 0.57
▸ PRKAG3 Q9UGI9 2/20 0.57
▸ PRKAG2 Q9UGJ0 2/20 0.57
▸ PRKAB1 Q9Y478 2/20 0.57
▸ BMPR1B O00238 1/20 0.57
▸ YES1 P07947 1/20 0.57
▸ THRB P10828 1/20 0.57
▸ EIF2AK2 P19525 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7618559 0.87 KDR (0.77) KDRFLT1FLT4BMP4PRKAB2
SCHEMBL7616736 0.86 KDR (1.00) KDRFLT1FLT4BMP4PRKAB2
SCHEMBL7616707 0.86 KDR (1.00) KDRFLT1FLT4BMP4PRKAB2
SCHEMBL7610636 0.85 KDR (1.00) KDRFLT1FLT4BMP4PRKAB1
SCHEMBL2059685 0.85 KDR (1.00) KDRFLT1FLT4BMP4PRKAB1
SCHEMBL7613010 0.82 KDR (0.76) KDRFLT1FLT4BMP4
SCHEMBL23988765 0.81 KDR (0.68) KDRFLT1FLT4BMP4PRKAB1
SCHEMBL23988761 0.80 KDR (0.67) KDRFLT1FLT4BMP4PRKAB1
SCHEMBL23988994 0.80 KDR (0.67) KDRFLT1FLT4BMP4PRKAB1
SCHEMBL7612194 0.80 KDR (0.79) KDRFLT1FLT4BMP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020041880-A1 Method of treating cancer DEFEO-JONES DEBORAH (US) 2002-04-11 — — US claimed
US-6235741-B1 ANTICANCER AGENTS; AUTOIMMUNE DISEASES MERCK & CO., INC. 2001-05-22 — — US claimed
EP-0984692-A4 NOVEL ANGIOGENESIS INHIBITORS MERCK & CO INC (US) 2001-02-21 — — EP claimed
EP-0984692-A1 NOVEL ANGIOGENESIS INHIBITORS Merck & Co., Inc. (US) 2000-03-15 — — EP claimed
WO-1998054093-A1 NOVEL ANGIOGENESIS INHIBITORS MERCK & CO., INC. (US) 1998-12-03 — — WO claimed
US-20230398118-A1 METHODS OF TREATING CARDIOVASCULAR-RELATED DISEASE KEROS THERAPEUTICS, INC. 2023-12-14 — — US disclosed
US-20230372390-A1 METHODS OF TREATING LYMPHOPENIA KEROS THERAPEUTICS, INC. 2023-11-23 — — US disclosed
US-20170014349-A1 TREATING SOFT TISSUE VIA CONTROLLED DRUG RELEASE UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2017-01-19 — — US disclosed
US-9523674-B2 Method of screening for substances capable of promoting induction of induced pluripotent stem cells NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) 2016-12-20 — — US disclosed
US-20160263117-A1 COMPOSITIONS AND METHODS FOR CARDIOVASCULAR DISEASE NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2016-09-15 — — US disclosed
US-9045484-B2 Inhibitors of the BMP signaling pathway THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2015-06-02 — — US disclosed
US-20140038953-A1 COMPOSITIONS AND METHODS FOR CARDIOVASCULAR DISEASE THE GENERAL HOSPITAL CORPORATION (US) 2014-02-06 — — US disclosed
US-8507501-B2 Inhibitors of the BMP signaling pathway THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2013-08-13 — — US disclosed
US-20110053930-A1 INHIBITORS OF THE BMP SIGNALING PATHWAY THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2011-03-03 — — US disclosed
US-6380203-B1 PYRAZOLO(1,5-A)PYRIMIDINE DERIVATIVES; TREATMENT OF TYROSINE KINASE-DEPENDENT DISEASES/CONDITIONS SUCH AS ANGIOGENESIS, CANCER, ATHEROSCLEROSIS, DIABETIC RETINOPATHY OR AUTOIMMUNE DISEASES MERCK & CO., INC. 2002-04-30 — — US disclosed
US-20020041880-A1 Method of treating cancer DEFEO-JONES DEBORAH (US) 2002-04-11 — — US disclosed
US-6235741-B1 ANTICANCER AGENTS; AUTOIMMUNE DISEASES MERCK & CO., INC. 2001-05-22 — — US disclosed
EP-0984692-A4 NOVEL ANGIOGENESIS INHIBITORS MERCK & CO INC (US) 2001-02-21 — — EP disclosed
EP-0984692-A1 NOVEL ANGIOGENESIS INHIBITORS Merck & Co., Inc. (US) 2000-03-15 — — EP disclosed
WO-1998054093-A1 NOVEL ANGIOGENESIS INHIBITORS MERCK & CO., INC. (US) 1998-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160263117-A1 COMPOSITIONS AND METHODS FOR CARDIOVASCULAR DISEASE APOB, BMP1, LDLR KDR 251/4885FLT1 121/4885FLT4 185/4885
US-20110053930-A1 INHIBITORS OF THE BMP SIGNALING PATHWAY BMP1, BMP2K, BMP2 KDR 260/4885FLT1 162/4885FLT4 129/4885
US-20170014349-A1 TREATING SOFT TISSUE VIA CONTROLLED DRUG RELEASE BMP2, BMP1, BMP6 KDR 203/4885FLT1 324/4885FLT4 542/4885
US-20230398118-A1 METHODS OF TREATING CARDIOVASCULAR-RELATED DISEASE BMPR2, BMP1, BMP2 KDR 138/4885FLT1 193/4885FLT4 203/4885
US-20140038953-A1 COMPOSITIONS AND METHODS FOR CARDIOVASCULAR DISEASE APOB, BMP1, LDLR KDR 251/4885FLT1 121/4885FLT4 185/4885
US-20020041880-A1 Method of treating cancer ACP3, FOLH1, KLK3 KDR 318/4885FLT1 118/4885FLT4 58/4885
US-20230372390-A1 METHODS OF TREATING LYMPHOPENIA HAMP, BMPR2, BMP2 KDR 1564/4885FLT1 818/4885FLT4 1345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.